Coya Therapeutics CEO Discusses Company's Treatment Pipeline
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a look at the organization's pipeline.
PE: Is there anything else in Coya’s pipeline that is the works that you would like to speak about?
Berman: Going back to 302, it's a pipeline. We call it a pipeline in a product. Imagine now being able to control many different conditions with that one combination approach. In addition to that, we're developing combination approaches with the low dose IL2 portion. We can now take IL2 and combine it with TNF alpha drugs, GMCSF, or other compounds that may be synergistic. It opens up a unique way to now have opportunities to slow inflammation, not necessarily just with the CTLA4 component or the abatacept, but in other capacities as well. That's very interesting to companies. Then of course, we have our exosomes, which we don't talk too much about, but it's a type of vesicle in the cell that we've been able to isolate, and it opens up opportunities to put things inside the exosomes or to target them to other proteins, tissues, or diseases of interest, and we're developing that in parallel.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
